Hepatic encephalopathy (maintenance treatment) - rifaximin: evaluation report 2

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

01 - Consultee comments on the ACD – British Liver Trust

02 - Consultee comments on the ACD – Foundation for Liver Research

03 - Consultee comments on the ACD – Norgine

04 - Consultee comments on the ACD – Royal College of Nursing

05 - Clinical expert comments on the ACD – Moreea

06 - Clinical expert comments on the ACD – Shawcross

07 - Public comments on the ACD received via the NICE website

08 - Additional evidence submitted by Norgine

09 - Review of additional evidence submitted by Peninsula Technology Assessment Group

10 – Statement submitted by Andrew Langford following sight of the committee papers

* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *

This page was last updated: 26 November 2013